

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
COLEMAN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/013728

FILED: 2 DECEMBER 2004

U.S. APPLICATION NO: 10/578,290

35 USC §371 DATE: 11 JANUARY 2007

FOR: PHARMACEUTICAL USES OF BISPHOSPHONATES

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852



Oona A. Jackson
Attorney for Applicants
Reg. No. 48,152

Date: 7/11/07

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33540-US-PCT
APPLICATION NO.
10/578,290
APPLICANT
COLEMAN ET AL.
FILING DATE
JANUARY 11, 2007

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	*WO 03/035081	5/1/03	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	*WO 2004/012728	2/12/04	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	*Algur et al., "Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines," International Journal of Radiation: Oncology Biology Physics, Pergamon Press US, Vol. 61(2), pp. 535-542 (2005)
	AS	*Jagdev et al., "The Bisphosphonate, Zoledronic Acid, Induces Apoptosis of Breast Cancer Cells: Evidence for Synergy with Paclitaxel," British Journal of Cancer, Vol. 8(84), pp. 1126-1134 (2001)
	AT	*Kokufu et al., "A case of effective bisphosphonate therapy of sequential pamidronate and incadronate for bone metastases from breast cancer!" Gan to Kagaku Ryoho, Cancer & Chemotherapy, Vol. 27(9), pp. 1425-1428 (2000)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33540-US-PCT
APPLICATION NO.
10/578,290
APPLICANT
COLEMAN ET AL.
FILING DATE
JANUARY 11, 2007

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	*Harvey H.A., "Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma," Cancer, American Cancer Society, Vol. 80(8), Suppl, pp. 1646-1651 (1997)
DB	*Harvey H.A., "Therapeutic use of bisphosphonates in breast cancer: Studies with zoledronic acid," American Journal of Cancer 2003, New Zealand, Vol. 2, No. Suppl. , pp. 19-25 (2003)
DC	*Freyer et al., "Palliative hormone therapy, low dose chemotherapy and bisphosphonate in breast cancer patients with bone marrow involvement and pancytopenia; report of pilot experience," European Journal of Internal Medicine, Vol. 11, pp. 329-333 (2000)
DD	*Neville-Webbe et al., "The combination of zoledronic acid (ZOL) and trail (tumor necrosis factor related apoptosis inducing ligand) has potential synergistic action in breast cancer cells (BCC," Clinical Oncology, Vol. 15 pp. S28-S29 (2003)
DE	Magnetto et al., "Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone," Int. J. Cancer, Vol. 83, pp. 263-269 (1999)
DF	Stearns et al., "Effects of Alendronate and Taxol on PC-3 ML Cell Bone Metastases in SCID Mice," Invasion Metastasis, No. 16, pp. 116-131 (1996)
DG	
DH	
DI	
DJ	
DK	
DL	
DM	
DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.